Giuseppe Curigliano to Middle Aged
This is a "connection" page, showing publications Giuseppe Curigliano has written about Middle Aged.
Connection Strength
0.056
-
Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer. Eur J Cancer. 2017 12; 87:164-171.
Score: 0.012
-
Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer. J Clin Oncol. 2017 Aug 10; 35(23):2600-2603.
Score: 0.012
-
Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. JCO Glob Oncol. 2021 02; 7:162-172.
Score: 0.004
-
Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer. Eur J Cancer. 2019 10; 120:1-9.
Score: 0.003
-
Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. Eur J Cancer. 2019 09; 118:41-48.
Score: 0.003
-
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 2019 03; 20(3):371-382.
Score: 0.003
-
Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients. Reprod Biomed Online. 2019 May; 38(5):835-844.
Score: 0.003
-
Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer. 2018 05; 94:126-137.
Score: 0.003
-
Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Lancet Oncol. 2018 03; 19(3):323-336.
Score: 0.003
-
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO. Eur J Cancer. 2018 01; 89:42-48.
Score: 0.003
-
Evaluation of inter-observer variability according to RECIST 1.1 and its influence on response classification in CT measurement of liver metastases. Eur J Radiol. 2017 Oct; 95:96-101.
Score: 0.003
-
Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. Acta Oncol. 2013 Nov; 52(8):1649-56.
Score: 0.002
-
A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients. Lung Cancer. 2006 Dec; 54(3):359-64.
Score: 0.001